Opinion|Videos|September 4, 2024
Transitioning to Alternative Therapies: Topoisomerase Inhibitors vs. Hypomethylating Agents
Author(s)Jamie L. Koprivnikar, MD, Solly Chedid, MD
Experts on lower-risk MDS discuss when to switch to a topoisomerase inhibitor versus going to a hypomethylating agent.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- When would you switch at this point to a topoisomerase inhibitor versus going to a hypomethylating agent?
Advertisement
Related to this article
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Real-World Data for Darolutamide vs Abiraterone Triplet Therapy in mHSPC
4
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
5